


SECURE Press release

October 2016

The H2020 project SECURE, or “Secondary prEvention of CardiovasCular disease in the Elderly trial”, has now been going on for eighteen months. SECURE is the first trial testing the efficacy of a fixed dose combination (FDC) polypill for secondary cardiovascular prevention in the elderly population (≥ 65 years old) as compared to standard therapy (the three components of the polypill given separately).

Before the clinical trial and the recruitment of patients could start, a preparatory phase needed to be completed with the following steps:

- Selection of centres according to different criteria in order to have the appropriate number in each country;
- Finalisation of the study protocol and all necessary documents to obtain approval from Ethics Committees and Competent Authorities;
- Production, labelling and shipment of the polypill to the sites;
- Opening of recruitment sites and training of investigators.



Highlight

Recruitment started at the end of August 2016 and 82 patients are now taking part in the SECURE clinical trial.

There are currently 43 active sites recruiting patients in all 7 countries of the study.

The list of active sites and their respective Principal Investigators is available under the description of each corresponding national coordinator [in the Partners section](#) of the public website.



The SECURE project brings together a consortium of 11 organisations from 8 different European countries:

- **CNIC, the Spanish National Centre for Cardiovascular Research**, is an international research centre of excellence, with the mission to improve cardiovascular health in the population, generating scientific knowledge and efficiently translating that knowledge to the clinic. CNIC is the Coordinator of the project.
- **IRFMN, Mario Negri Institute for Pharmacological Research**, a non-profit independent scientific organisation for pharmacological and biomedical research and education whose aim is to improve the quality of human health and life, coordinates the centres participating in the study in Italy.
- **Charité University**, the largest university hospital in Europe, acts as country coordinator in Germany.
- The **University Hospital of Besançon**, with two hospitals carrying out tasks of care, prevention, education and research, is the national co-sponsor for the clinical trial in France.
- **Wroclaw Medical University**, whose Heart Diseases department is a world recognized expert in the field of treatment of chronic and acute heart failure, coordinates the study in Poland.
- **Semmelweis University**, with over 240 years of tradition of medical education, clinical and preclinical research, is the national coordinator of the clinical trial in Hungary.
- The **General University Hospital in Prague**, one of the largest hospitals in the Czech Republic providing a highly specialized care particularly in cardiology, acts as country coordinator in Czech Republic.
- **SERMAS, Madrid Health Service**, representing Hospital Clínico San Carlos, a national and international reference centre, coordinates the study in Spain together with CNIC.
- The **London School of Hygiene and Tropical Medicine**, whose Department of Medical Statistics is a worldwide leader in this profession, is leading all statistical aspects of the project.
- **ARTTIC**, with a 29-year track record in management of international R&D collaboration projects, assists CNIC in the project management and leads the dissemination and communication activities.
- **Ferrer**, an international pharmaceutical company, is responsible for providing the polypill medication.

*For more information about SECURE,
please visit <http://www.secure-h2020.eu/>
and subscribe to the RSS feed to get the latest updates!*

*You can also download documents published by the project, including
the brochure in all 7 languages of the study*

